February 9, 2023
Santen Pharmaceutical said on February 8 that Chinese regulatory authorities have accepted for review an application seeking approval for its glaucoma and ocular hypertension treatment STN1011101 (tafluprost + timolol), known as Tapcom in Japan. The drug is a preservative-free combination...read more